Dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase

Journal of Steroid Biochemistry and Molecular Biology

Volumn 110, Issue 3-5, 2008, Pages 214-222

  Attardi, Barbara J ^a   Pham, Trung C ^a   Radler, Lisa M ^a   Burgenson, Janet ^a   Hild, Sheri A ^a   Reel, Jerry R ^a  

^a BIOQUAL INC   (United States)

Author keywords

19 Norandrogens; C19 androgens; Estrogen receptors; Hormonal therapy for men; Human aromatase; Transcription

Indexed keywords

11BETA METHYL 19 NORTESTOSTERONE; 11BETA METHYLESTRADIOL; 16ALPHA HYDROXYANDROSTENEDIONE; 16ALPHA HYDROXYESTRONE; 17 METHYLESTRADIOL; 17ALPHA METHYTESTOSTERONE; 19 NORPROGESTIN; 19 NORSTEROID; 7ALPHA METHYLESTRADIOL; 7ALPHA,11BETA DIMETHYLESTRADIOL; ACETONITRILE; ANDROGEN; ANDROSTENEDIONE; AROMATASE; CDB 1321; DIMETHANDROLONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; ETHINYLESTRADIOL; LETROZOLE; NANDROLONE; NANDROLONE DERIVATIVE; NORETHISTERONE; PROGESTERONE DERIVATIVE; TESTOSTERONE; TRESTOLONE; 11 METHYL 19 NORTESTOSTERONE; 11-METHYL-19-NORTESTOSTERONE; 7ALPHA,11BETA DIMETHYL 19 NORTESTOSTERONE; 7ALPHA,11BETA-DIMETHYL-19-NORTESTOSTERONE; DRUG DERIVATIVE; ESTRANE DERIVATIVE; METHYLESTRENOLONE; RECOMBINANT PROTEIN;

AROMATIZATION; ARTICLE; BINDING ASSAY; BREAST CANCER; CANCER CELL; CENTRIFUGATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; HUMAN; HUMAN CELL; INCUBATION TIME; LIGHT ABSORPTION; RECEPTOR AFFINITY; SYNTHESIS; BIOLOGICAL MODEL; CELL CULTURE; CYCLIZATION; METABOLISM;

ANDROGENS; AROMATASE; CYCLIZATION; ESTRADIOL; ESTRENES; HUMANS; MODELS, BIOLOGICAL; NANDROLONE; RECOMBINANT PROTEINS; TESTOSTERONE; TUMOR CELLS, CULTURED;

EID: 44849091208     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.11.009     Document Type: Article

References (42)

1. Byrne M.M., and Nieschlag E. Testosterone replacement therapy in male hypogonadism. J. Endocrinol. Invest. 26 (2003) 481-489
2. Oettel M. The endocrine pharmacology of testosterone therapy in men. Naturwissenschaften 91 (2004) 66-76
3. Attardi B.J., Hild S.A., and Reel J.R. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 147 (2006) 3016-3026
4. Simpson E.R., Mahendroo M.S., Means G.D., Kilgore M.W., Hinshelwood M.M., Graham-Lorence S., Amarneh B., Ito Y., Fisher C.R., Michael M.D., Mendelson C.R., and Bulun S.E. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Rev. 15 (1994) 342-355
5. de Gooyer M.E., Oppers-Tiemissen H.M., Leysen D., Verheul H.A.M., and Kloosterboer H.J. Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): Analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 68 (2003) 235-243
6. Hong Y., Yu B., Sherman M., Yuan Y.-C., Zhou D., and Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol. Endocrinol. 21 (2007) 401-414
7. Tan L., and Muto N. Purification and reconstitution of human placental aromatase A cytochrome P-450-type monooxygenase. Eur. J. Biochem. 156 (1986) 243-250
8. Silberzahn P., Gaillard J.L., Quincey D., Dintinger T., and Al-Timimi I. Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes: differences from human placental microsomes. J. Steroid Biochem. 29 (1988) 119-125
9. Dintinger T., Gaillard J.L., Moslemi S., Zwain I., and Silberzahn P. Androgen and 19-norandrogen aromatization by equine and human placental microsomes. J. Steroid Biochem. 33 (1989) 949-954
10. Amri H., Gaillard J.L., Al-Timimi I., and Zilberzahn P. Equine ovarian aromatase: evidence for a species specificity. Biochem. Cell Biol. 71 (1993) 296-302
11. Khalil M.W., Chung N., Morley P., Glasier M.A., and Armstrong D.T. Formation and metabolism of 5(10)-estrene-3 beta, 17 beta-diol, a novel 19-norandrogen produced by porcine granulosa cells from C19 aromatizable androgens. Biochem. Biophys. Res. Commun. 155 (1988) 144-150
12. Raeside J.L., Renaud R.L., and Friendship R.M. Aromatization of 19-norandrogens by porcine Leydig cells. J. Steroid Biochem. 32 (1989) 729-735
13. LaMorte A., Kumar N., Bardin C.W., and Sundaram K. Aromatization of 7-alpha-methyl-19-nortestosterone by human placental microsomes in vitro. J. Steroid Biochem. Mol. Biol. 48 (1994) 297-304
14. Sundaram K., Kumar N., Monder C., and Bardin C.W. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. J. Steroid Biochem. Mol. Biol. 53 (1995) 253-257
15. Attardi B.J., Burgenson J., Hild S.A., and Reel J.R. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 88 (2004) 277-288
16. Raobaikady B., Parsons M.F.C., Reed M.J., and Purohit A. Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative. Steroids 71 (2006) 639-646
17. Mor G., Eliza M., Song J., Wiita B., Chen S., and Naftolin F. 17α-Methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. J. Steroid Biochem. Mol. Biol. 79 (2001) 239-246
18. Covey D.F., and Hood W.F. Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108 (1981) 1597-1599
19. Larrea F., Garcia-Becerra R., Lemus A.E., Garcia G.A., Perez-Palacios G., Jackson K.J., Coleman K.M., Dace R., Smith C.L., and Cooney A.J. A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha. Endocrinology 142 (2001) 3791-3799
20. Garcia-Becerra R., Borja-Cacho E., Cooney A.J., Smith C.L., Lemus A.E., Perez-Palacios G., and Larrea F. Synthetic 19-nortestosterone derivatives as estrogen receptor alpha subtype-selective ligands induce similar receptor conformational changes and steroid receptor coactivator recruitment than natural estrogens. J. Steroid Biochem. Mol. Biol. 99 (2006) 108-114
21. Perez-Palacios G., Santillian R., Garcia-Becerra R., Borja-Cacho E., Larrea F., Damian-Matsumura P., Gonzalez L., and Lemus A.E. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern. J. Endocrinol. 190 (2006) 805-818
22. Attardi B.J., Hild S.A., Koduri S., Pham T., Pessaint L., Engbring J., Till B., Gropp D., Semon A., and Reel J.R. Dimethandrolone (DMA: 7α,11β-dimethyl-19-nortestosterone) does not require 5α-reduction to exert its maximal biological effects. Program of the 89th Annual Meeting of the Endocrine Society. Toronto, Canada (2007) (Abstract P3-399)
23. Reel J.R., Lamb IV J.C., and Neal B.H. Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fund. Appl. Toxicol. 34 (1996) 288-305
24. Hershberger L.G., Shipley E.G., and Meyer R.K. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc. Soc. Exp. Biol. Med. 83 (1953) 175-180
25. Sudhir K., and Komesaroff P.A. Cardiovascular actions of estrogens in men. J. Clin. Endocrinol. Metab. 84 (1999) 3411-3415
26. Thompson D., and Carter J. Drug-induced gynecomastia. Pharmacotherapy 13 (1993) 37-45
27. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., and Ohlsson C. Androgens and bone. Endocrine Rev. 25 (2004) 389-425
28. Szulc P., Munoz F., Claustrat B., Garnero P., Marchand F., Duboeuf F., and Delmas P.D. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J. Clin. Endocrinol. Metab. 86 (2001) 192-199
29. Amin S. Low estradiol levels linked to low-trauma hip fractures in men. Am. J. Med. 119 (2006) 426-433
30. Kawano H., Sato T., Yamada T., Matsumoto T., Sekine K., Watanabe T., Nakamura T., Fukuda T., Yoshimura K., Yoshizawa T., Aihara K., Yamamoto Y., Nakamichi Y., Metzger D., Chambon P., Nakamura K., Kawaguchi H., and Kato S. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9416-9421
31. Vandenput L., Swinnen J.V., Boonen S., Van Herck E., Erben R.G., Bouillon R., and Vanderschueren D. Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J. Bone Miner. Res. 19 (2004) 1462-1470
32. Danilovic D.L., Correa P.H., Costa E.M., Melo K.F., Mendonca B.B., and Arnhold I.J. Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene. Osteoporosis Int. 18 (2007) 369-374
33. Sobel V., Schwartz B., Zhu Y.S., Cordero J.J., and Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J. Clin. Endocrinol. Metab. 91 (2006) 3017-3023
34. Tracz M.J., Sideras K., Bolona E.R., Haddad R.M., Kennedy C.C., Uraga M.V., Caples S.M., Erwin P.J., and Montori V.M. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J. Clin. Endocrinol. Metab. 91 (2006) 2011-2016
35. Venken K., Boonen S., Van Herck E., Vandenput L., Kumar N., Sitruk-Ware R., Sundaram K., Bouillon R., and Vanderschueren D. Bone and muscle protective potential of the prostate-sparing synthetic androgen 7α-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone 36 (2005) 663-670
36. Wranicz J.K., Cygankiewicz I., Kula P., Walczak-Jeedrzejowska R., Sllowikowska-Hilczer J., and Kula K. Cardiovascular and metabolic effects of estrogen in men. Archives Med. Sci. 4 (2006) 221-225
37. Lindzey J., Wetsel W.C., Couse J.F., Stoker T., Cooper R., and Korach K.S. Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice. Endocrinology 139 (1998) 4092-4101
38. Wersinger S.R., Haisenleder D.J., Lubahn D.B., and Rissman E.F. Steroid feedback on gonadotropin release and pituitary gonadotropin subunit mRNA in mice lacking a functional estrogen receptor alpha. Endocrine 11 (1999) 137-143
39. Temple J.L., Scordalakes E.M., Bodo C., Gustafsson J.A., and Rissman E.F. Lack of functional estrogen receptor beta gene disrupts pubertal male sexual behavior. Horm. Behav. 44 (2003) 427-434
40. Harkonen P.L., and Makela S.I. Role of estrogens in development of prostate cancer. J. Steroid Biochem. Mol. Biol. 92 (2004) 297-302
41. Bosland M.C. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev. Urol. 7 (2005) S4-S10
42. Geerlings M.I. Endogenous sex hormones, cognitive decline, and future dementia in old men. Ann. Neurol. 60 (2006) 346-355